Daniel M. Himmel - Resume 10-19-2015 Structure-based Drug Discovery.pdf

File uploaded by Daniel Himmel on Aug 4, 2015Last modified by Daniel Himmel on Oct 20, 2015
Version 2Show Document
  • View in full screen mode

                                                                                                                                                            August 4, 2015

I can take your research project from PCR and protein expression right through to structure determination and the early stages of structure-based drug discovery and design. The expertise that I offer is team leadership and experience with PCR, protein expression and purification, as well as robotic high-throughput X-ray crystallography with extensive background in structure determination, structural biological analysis, structure-activity-relationship (SAR) analysis, as well as related computational chemistry analysis, including induced-fit docking of ligands. My previous work has targeted HIV, and I am currently interested in targeting enzymes of pathogenic bacteria.

The experience I bring you draws on the highly collaborative interdisciplinary research environments of the New York Structural Genomics Research Consortium at Albert Einstein College of Medicine (which I helped to coordinate during my position there) and the laboratory of Eddy Arnold at the Center for Advanced Biotechnology & Medicine, Rutgers University. A collaboration of the Arnold laboratory with industry, Dr. Paul Janssen, and others has recently led to the development of rilpivirine and etravirine, two of among the most effective anti-AIDS drugs in the clinic to date. During that development, I conducted widely-cited structure determination and SAR analysis of inhibitor analogs of rilpivirine. I have spearheaded an effort to lay the groundwork for the same kind of structure-based small molecule drug discovery to develop a new class of inhibitor lead compounds for the treatment of drug-resistant strains of HIV-1, in collaboration with researchers in both the public and private sectors. My most significant contributions in these efforts have included the first structures for complexes of the HIV-1 enzyme reverse transcriptase (RT) with both allosteric and active site inhibitors of the enzyme's RNase H activity. These studies have led to improved inhibitors with submicromolar activity. I have served as a co-editor for the second edition of the International Tables for Crystallography Volume F.

I would welcome the opportunity to meet with you to discuss how your R&D project might benefit from the expertise and skills that I can offer.